1st-of-its-kind therapy blocks immune attack after stem-cell transplant
A midstage clinical trial suggests that a "first-of-its-kind" treatment could prevent serious immune attacks from bone-marrow transplants.
Stay updated with breaking news from Ivan Maillard. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
A midstage clinical trial suggests that a "first-of-its-kind" treatment could prevent serious immune attacks from bone-marrow transplants.
An experimental antibody treatment largely prevented a bone marrow transplant complication called graft versus host disease (GVHD) in the intestines, without causing broad immune suppression, in a preclinical study led by researchers from Penn Medicine and Dana-Farber/Boston Children's Cancer and Blood Disorders Center and published today in Science Translational Medicine.
E-Mail PHILADELPHIA--Patients with inactive cancer and not currently undergoing treatments also face a significantly higher risk of severe illness from COVID-19, a new study from Penn Medicine published online today in JNCI Cancer Spectrum shows. Past reports have established an increased risk of severe disease and death for sick or hospitalized cancer patients with COVID-19 compared to patients without cancer, but less is known about patients in the general population. The findings underscore the importance of COVID-19 mitigation, like social distancing and mask wearing, and vaccination...